Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Teva pharmaceutical industries ltd symbols : Kmda save search
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Published: 2024-04-19 (Crawled : 10:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 1.16%
H: 7.28%
C: 1.3%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
humira biosimilar approved for agreement
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 2.98%
H: 0.17%
C: -0.43%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.18%
H: 2.16%
C: 0.9%
audio
Alvotech Announces Increase in Number of Own Shares
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
| Email alert
Add to watchlist
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
| Email alert
Add to watchlist
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -1.58%
H: 1.87%
C: 0.53%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: -1.86%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.58%
H: 1.2%
C: 0.84%
business year update financial results
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -0.99%
H: 0.75%
C: -0.13%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -6.12%
H: 1.67%
C: 1.17%
year financial results
Alvotech Appoints Interim Chief Quality Officer
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -0.58%
H: 3.04%
C: 3.01%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -1.27%
H: 2.97%
C: 2.41%
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
Published: 2024-02-26 (Crawled : 10:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 11.35%
H: 0.84%
C: -3.25%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.0%
H: 1.6%
C: -0.49%
million
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
| Email alert
Add to watchlist
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
Published: 2024-02-15 (Crawled : 12:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 0.32%
H: 2.98%
C: 0.32%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 1.66%
H: 1.96%
C: 0.49%
avt04 stelara biosimilar expected global market
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
Published: 2024-01-19 (Crawled : 17:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 6.64%
H: 11.54%
C: 8.1%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.85%
H: 1.46%
C: 0.69%
avt02 avt04 license update
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
Published: 2024-01-10 (Crawled : 09:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -0.72%
H: 1.77%
C: -1.53%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.66%
H: 0.71%
C: 0.17%
first biosimilar approval stelara
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
Published: 2024-01-03 (Crawled : 09:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 1.23%
H: 2.17%
C: 1.57%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.97%
H: 1.53%
C: 0.0%
avt06 eylea candidate biosimilar results study
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Published: 2023-11-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
avt05 simponi biosimilar positive results study
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.18%
H: 0.12%
C: -0.16%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.35%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
business update financial results
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.35%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
business update financial results
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
Published: 2023-11-21 (Crawled : 13:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -2.08%
H: 1.94%
C: 0.67%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.21%
H: 1.06%
C: 0.85%
conference report business update financial results
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 0.33%
H: 3.87%
C: -0.55%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.21%
H: 1.67%
C: 1.25%
avt04 stelara pharma biosimilar authorization
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
Published: 2023-11-10 (Crawled : 14:30) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 0.12%
H: 7.18%
C: 3.56%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.22%
H: 0.86%
C: 0.86%
biosimilar chmp positive stelara
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.